Molecular MOLN 深 沪
已收盘 10-09 16:00:00 美东时间
3.85
+0.040
+1.05%
华盛通- 最 高3.88
- 今 开3.74
- 成交量 5747股
- 最 低 3.53
- 昨 收 3.81
- 总市值 1.47亿
- 52周最高 5.36
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 3.53
- 委 比 53.85%
- 总股本 3830.52万
- 历史最高 32.04
- 量 比 4.68
- 振 幅 9.19%
- 历史最低 3.32
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Quanome’s XDT Secures First Enterprise Customer Agreement for Dedicated AI Inference Services
Quanome Technologies' subsidiary, XDT Infrastructure I, LLC, has signed a 60-month agreement with an enterprise customer for dedicated AI inference services, with a total commitment exceeding $100 million. The customer will remotely access AI computing capacity managed by XDT, avoiding the need to own and operate its own AI infrastructure. This marks Quanome's transition from planning AI infrastructure to delivering long-term managed services. Ad...
10-08 18:40
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
VERAXA Biotech AG is implementing FDA-aligned New Approach Methodologies (NAMs) to accelerate its oncology pipeline and reduce animal testing. NAMs, including cell-based assays, organ-on-chip systems, and computational modeling, enable more human-relevant data and faster development. VERAXA has already integrated NAMs into its preclinical programs, showcasing superior safety and efficacy in BiTAC-based therapies. The company's use of patient-deri...
10-07 11:00
Harvard Bioscience Announces Creation of Scientific Advisory Board
Harvard Bioscience, Inc. has established a Scientific Advisory Board (SAB) to guide its research, development, and new product strategies. The SAB includes five members: CEO John Duke, Dr. Ryan Conder of STEMCELL Technologies, Dr. Aaron Goldman of Harvard Medical School, Dr. Keith Olson of Ananda Devices, and Eric Richman of LabConnect and SafeHeal. This board aims to enhance the company's R&D and product innovation, leveraging expertise in drug ...
10-06 20:05
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
Radiopharm Theranostics announced the successful completion of an End-of-Phase 2 meeting with the FDA for RAD101, its investigational imaging agent for detecting brain metastases. RAD101 demonstrated 93% concordance with MRI in Phase 2b trials. The company expects FDA meeting minutes within 30 days and is advancing Phase 3 readiness activities. RAD101 has received FDA Fast Track Designation and is being developed to address unmet needs in brain m...
10-05 12:00
4DMT to Host Investor Day on October 21, 2026
4DMolecular Therapeutics will host an Investor Day on October 21, 2026, in New York City, featuring insights on 4D-150's clinical profile and commercial vision, as well as discussions with leading retinal experts. The event will include a Company presentation, expert panel sessions, and a Q&A. Registration is available online, and an archived webcast will be accessible for up to one year. 4D-150 is a sustained-release anti-VEGF therapy for retina...
10-05 12:00
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Abivax will present seven scientific abstracts on obefazimod, its lead drug candidate for treating moderately to severely active ulcerative colitis, at the United European Gastroenterology (UEG) Week 2026 in Barcelona. The presentations include data from Phase 3 ABTECT Maintenance and Induction trials, long-term Phase 2 findings, and preclinical research on obefazimod's anti-fibrotic and anti-tumor activity. The company highlights the potential o...
09-30 20:05
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Sutro Biopharma appointed Lucas Donigian as Senior Vice President, Business Development, leveraging his 20+ years of biotech experience, including over $2B in oncology partnerships. Donigian will help advance Sutro’s ADC platform and pipeline, including STRO-004, STRO-006, and STRO-227, while building strategic collaborations. He previously led business development at Zymeworks and NanoString Technologies. Sutro granted Donigian stock options and...
09-29 12:00
Insight Molecular Diagnostics Revises Chronix Royalty Agreement Terms
Insight Molecular Diagnostics ( ($IMDX) ) has issued an announcement. Insight M...
09-22 04:59
The FDA Posted Briefing Documents For Grails Galleri Test Review Ahead Of The Molecular And Clinical Genetics Panel Of The Medical Devices Advisory Committee That Is Being Held On September 23; Flags No Major Concerns For Co's Cancer Test
https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting
09-21 23:52
InflaRx to Host Virtual Capital Markets Day
InflaRx N.V. will host a virtual Capital Markets Event on November 3, 2026, from 8:00 AM EST to 9:00 AM EST, featuring Peter A. Merkel, MD, MPH, and Prof. Dr. Jörg Köhl. The event will discuss ANCA-associated vasculitis (AAV), the evolving treatment landscape, and the potential of izicopan, an orally administered C5a receptor inhibitor, to improve the standard of care. Key topics include InflaRx's development strategy, clinical program updates, a...
09-21 11:30
